ArticleBMC microbiology2014
Bdellovibrio bacteriovorus HD100 guards against Pseudomonas tolaasii brown-blotch lesions on the surface of post-harvest Agaricus bisporus supermarket mushrooms.
Article in BMC microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Bdellovibrio and Like Organisms (BALOs): Biology, Predatory Mechanisms, and Bioindustrial Potential.World journal of microbiology & biotechnology · 2026Review
- The Predatory BacteriaMicroorganisms · 2026Article
- From microbes to animals: a review on prey choice and prey-predator dynamics across organismal scales.FEMS microbiology reviews · 2026Review
- A molecular toolbox to modulate gene expression and protein secretion in the bacterial predator Bdellovibrio bacteriovorus.PLoS genetics · 2025Article
- Predatory potentials of novel3 Biotech · 2025Article
- Controlling the expression of heterologous genes in Bdellovibrio bacteriovorus using synthetic biology strategies.Microbial biotechnology · 2024Article
- Predatory bacteria as potential biofilm control and eradication agents in the food industry.Food science and biotechnology · 2023Review
- Moving toward a better understanding of the model bacterial predatorMicrobiology (Reading, England) · 2023Article
- Self-demise of soft rot bacteria by activation of microbial predators by pectin-based carriers.Microbial biotechnology · 2023Article
- Biosynthesis of silver nanoparticles using Pseudomonas canadensis, and its antivirulence effects against Pseudomonas tolaasii, mushroom brown blotch agent.Scientific reports · 2023Article
- Identification of NpdA as the protein forming the surface layer inAccess microbiology · 2023Article
- Interaction ofMicroorganisms · 2022Article
- Review
- The role of mathematical modelling in understanding prokaryotic predation.Frontiers in microbiology · 2022Review
- The potential of facultative predatoryFrontiers in microbiology · 2022Review
- Predatory and biocontrol potency of Bdellovibrio bacteriovorus toward phytopathogenic strains of Pantoea sp. and Xanthomonas campestris in the presence of exo-biopolymers: in vitro and in vivo assessments.International microbiology : the official journal of the Spanish Society for Microbiology · 2021Article
- Insights into Bdellovibrio spp. mechanisms of action and potential applications.World journal of microbiology & biotechnology · 2021Review
- Response of Pine Rhizosphere Microbiota to Foliar Treatment with Resistance-Inducing Bacteria against Pine Wilt Disease.Microorganisms · 2021Article
- Helper bacteria halt and disarm mushroom pathogens by linearizing structurally diverse cyclolipopeptides.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Potential Control of Potato Soft Rot Disease by the Obligate PredatorsApplied and environmental microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas tolaasii is a problematic pathogen of cultured mushrooms, forming dark brown 'blotches' on mushroom surfaces and causing spoilage during crop growth and post-harvest . Treating P. tolaasii infection is difficult, as other, commensal bacterial species such as Pseudomonas putida are necessary for mushroom growth, so treatments must be relatively specific.
resultsWe have found that P. tolaasii is susceptible to predation in vitro by the δ-proteobacterium Bdellovibrio bacteriovorus. This effect also occurred in funga, where B. bacteriovorus was administered to post-harvest mushroom caps before and after administration of the P. tolaasii pathogen. A significant, visible improvement in blotch appearance, after incubation, was observed on administration of Bdellovibrio. A significant reduction in viable P. tolaasii cell numbers, recovered from the mushroom tissue, was detected. This was accompanied by a more marked reduction in blotch severity on Bdellovibrio administration. We found that there was in some cases an accompanying overgrowth of presumed-commensal, non-Pseudomonas bacteria on post-harvest mushroom caps after Bdellovibrio-treatment. These bacteria were identified (by 16SrRNA gene sequencing) as Enterobacter species, which were seemingly resistant to predation. We visualised predatory interactions occuring between B. bacteriovorus and P. tolaasii on the post-harvest mushroom cap surface by Scanning Electron Microscopy, seeing predatory invasion of P. tolaasii by B. bacteriovorus in funga. This anti-P. tolaasii effect worked well in post-harvest supermarket mushrooms, thus Bdellovibrio was not affected by any pre-treatment of mushrooms for commercial/consumer purposes.
conclusionsThe soil-dwelling B. bacteriovorus HD100 preys upon and kills P. tolaasii, on mushroom surfaces, and could therefore be applied to prevent spoilage in post-harvest situations where mushrooms are stored and packaged for sale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.